Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig monotherapy in previously untreated unresectable pleural mesothelioma
CTR20260940Phase 2Active
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in pleural mesothelioma, sponsored by AstraZeneca. Started May 2026; status: active.
02
Drugs
volrustomig
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on CTR20260940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260940.